Rimantadine

DB00478ApprovedSmall moleculeInfluenza A M2 Protein Inhibitor

Rimantadine is an RNA synthesis inhibitor used to prevent influenza A infection.

Mechanism: The mechanism of action of rimantadine is not fully understood. Rimantadine appears to exert its inhibitory effect early in the viral replicative cycle, possibly inhibiting the uncoating of the virus. The protein coded by the M2 gene of influenza A may play an important role in rimantadine susceptibility.
Curator reviewed
Primary indication: For the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults.Curator reviewed · 4 structured indications
Formula / weight: C₁₂H₂₁N · 179.3018 g/mol (avg)
First approval: United States, 1993
Also known as: alpha-Methyladamantanemethylamine

Resolves to

Compound

UNII0T2EF4JQTUCAS13392-28-4ChEMBLCHEMBL959ChEBI94440PubChem5071KEGGD08483

Clinical / RWD

RxNorm9386ATCJ05AC02PharmGKBPA164748038

Structure

InChIKeyUBCHPRBFMUDMNC-UHFFFAOYSA-NSMILESCC(N)C12CC3CC(CC(C3)C1)C2

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

4Structured indicationsCondition, population, route and combination as fields, not prose

12Marketed productsAcross 1 country and 11 labellers

1ATC codeIncluding every combination product, plus 11 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rimantadine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In